Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 capsules in active psoriatic arthritis (Phase II)
CTR20260426Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH3906 in psoriatic arthritis (PsA), sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
TQH3906
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20260426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260426.